Michael R Megna is CHIEF ACCOUNTING OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 26,435 shares of KNSA, which is worth approximately $660,610. The most recent transaction as insider was on Sep 02, 2024, when has been sold 329 shares (Class A Ordinary Share) at a price of $26.74 per share, resulting in proceeds of $8,797. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 26.4K
23.95% 3M change
56.59% 12M change
Total Value Held $660,610

Michael R Megna Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 02 2024
SELL
Payment of exercise price or tax liability
$8,797 $26.74 p/Share
329 Reduced 1.23%
26,435 Class A Ordinary Share
Sep 02 2024
BUY
Exercise of conversion of derivative security
-
775 Added 2.81%
26,764 Class A Ordinary Share
Sep 01 2024
SELL
Payment of exercise price or tax liability
$73,668 $26.74 p/Share
2,755 Reduced 9.58%
25,989 Class A Ordinary Share
Sep 01 2024
BUY
Exercise of conversion of derivative security
-
6,490 Added 18.42%
28,744 Class A Ordinary Share
Jul 15 2024
BUY
Grant, award, or other acquisition
$7,512 $15.65 p/Share
480 Added 2.11%
22,254 Class A Ordinary Share
Apr 08 2024
SELL
Payment of exercise price or tax liability
$29,821 $17.9 p/Share
1,666 Reduced 7.25%
21,328 Class A Common Share
Apr 08 2024
BUY
Exercise of conversion of derivative security
-
3,932 Added 14.6%
22,994 Class A Common Share
Apr 01 2024
SELL
Payment of exercise price or tax liability
$21,354 $19.7 p/Share
1,084 Reduced 5.38%
19,062 Class A Common Share
Apr 01 2024
BUY
Exercise of conversion of derivative security
-
2,558 Added 11.27%
20,146 Class A Common Share
Mar 01 2024
SELL
Open market or private sale
$207,185 $21.45 p/Share
9,659 Reduced 35.45%
17,588 Class A Common Share
Mar 01 2024
BUY
Exercise of conversion of derivative security
$109,726 $11.36 p/Share
9,659 Added 26.17%
27,247 Class A Common Share
Feb 28 2024
SELL
Open market or private sale
$111,695 $21.79 p/Share
5,126 Reduced 22.57%
17,588 Class A Common Share
Feb 28 2024
BUY
Exercise of conversion of derivative security
$45,262 $8.83 p/Share
5,126 Added 18.41%
22,714 Class A Common Share
Jan 15 2024
BUY
Grant, award, or other acquisition
$7,200 $12.35 p/Share
583 Added 3.21%
17,588 Class A Common Share
Jan 02 2024
SELL
Open market or private sale
$319,563 $19.17 p/Share
16,670 Reduced 49.5%
17,005 Class A Common Share
Jan 02 2024
BUY
Exercise of conversion of derivative security
$231,379 $13.88 p/Share
16,670 Added 33.11%
33,675 Class A Common Share
Dec 19 2023
SELL
Open market or private sale
$178,215 $19.13 p/Share
9,316 Reduced 35.39%
17,005 Class A Common Share
Dec 19 2023
BUY
Exercise of conversion of derivative security
$129,306 $13.88 p/Share
9,316 Added 26.14%
26,321 Class A Common Share
Oct 04 2023
SELL
Payment of exercise price or tax liability
$832 $16.01 p/Share
52 Reduced 0.3%
17,005 Class A Common Share
Oct 04 2023
BUY
Exercise of conversion of derivative security
-
175 Added 1.02%
17,057 Class A Common Share
Sep 02 2023
SELL
Payment of exercise price or tax liability
$4,049 $17.76 p/Share
228 Reduced 1.33%
16,882 Class A Common Share
Sep 02 2023
BUY
Exercise of conversion of derivative security
-
774 Added 4.33%
17,110 Class A Common Share
Sep 01 2023
SELL
Payment of exercise price or tax liability
$20,512 $17.76 p/Share
1,155 Reduced 6.6%
16,336 Class A Common Share
Sep 01 2023
BUY
Exercise of conversion of derivative security
-
3,933 Added 18.36%
17,491 Class A Common Share
Jul 15 2023
BUY
Grant, award, or other acquisition
$7,175 $12.35 p/Share
581 Added 4.11%
13,558 Class A Common Share
MRM

Michael R Megna

CHIEF ACCOUNTING OFFICER
Hamilton, D0

Track Institutional and Insider Activities on KNSA

Follow Kiniksa Pharmaceuticals, Ltd. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA